RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00. That is more that 5X from the current price.